Sort by
Refine Your Search
-
Researcher will be based out of either the Boston, MA or Portland, ME campus and conduct applied research, prepare work for submission to journal/conference publications, contribute to extramural funding
-
, and scholarly activities. In partnership with Northeastern University, Intellia Therapeutics is offering a two-year Global Medical Affairs fellowship, based in Cambridge, MA. About Intellia Intellia
-
, and teaching. In partnership with Northeastern University, Alnylam is offering a two-year Regulatory Affairs PharmD fellowship based in Cambridge, Massachusetts. About Alnylam: Alnylam Pharmaceuticals
-
to strengths-based research that advances health equity for youth of color and their families using community engaged practices. The CHANGE lab, which is housed in the IHESJR, has areas of focus ranging across
-
, empirical and structure-based target design, synthetic chemistry and troubleshooting. Our main focuses are to improve the potency/efficacy and physicochemical as well as pharmacokinetics properties of the hit
-
, and scholarly activities. In partnership with Northeastern University, Alnylam Pharmaceuticals is offering a two-year Regulatory Affairs fellowship, based in Cambridge, MA. About Alnylam Alnylam
-
- Plasma Derived Therapy fellowship, based in Cambridge, MA. About Takeda Takeda has been translating science into breakthrough medicines for 240 years. Every step of the way, our teams have worked together
-
Affairs PharmD fellowship, based remotely. About Abbott Diabetes Care As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our
-
Global Medical Affairs fellowship, based in Waltham, MA. About Apellis Pharmaceuticals Apellis is delivering life-changing medicines across a broad range of serious diseases through the complement cascade
-
Global Medical Information fellowship, based in Cambridge, MA. About Alnylam Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative